Compare PL & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PL | AXSM |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | 970 | 925 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 12.0B |
| IPO Year | N/A | 2015 |
| Metric | PL | AXSM |
|---|---|---|
| Price | $41.29 | $227.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 17 |
| Target Price | $27.64 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 7.8M | 849.8K |
| Earning Date | 06-03-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.29 | $57.24 |
| Revenue Next Year | $30.22 | $55.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $96.09 |
| 52 Week High | $43.31 | $235.92 |
| Indicator | PL | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 57.77 | 68.50 |
| Support Level | $32.23 | $148.87 |
| Resistance Level | $41.71 | $234.29 |
| Average True Range (ATR) | 3.73 | 10.61 |
| MACD | 0.21 | 0.84 |
| Stochastic Oscillator | 65.91 | 83.59 |
Planet Labs PBC is an Earth-imaging company. It uses space to help life on Earth by imaging the world every day and making change visible, accessible, and actionable. Its platform includes imagery, insights, and machine learning that empower companies, governments, and communities around the world to make timely decisions about the evolving world. Its solutions are Broad Area Management. Its products are Planet Monitoring, Planet Tasking, Planet Analytic Feeds, Planetary Variables, Planet Basemaps, Planet Insights, and Platform Pricing. The group provides solutions to the Agriculture Science Program, Energy & Infrastructure, Forestry & Land Use, Mapping, Sustainability, Maritime, Civil Government, U.S. State and Local, Europe, Planet Federal, Defense & Intelligence, and Armed Services.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.